Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: Preliminary clinical results

Technology in Cancer Research and Treatment

Volumn 9, Issue 5, 2010, Pages 473-477

  Bolzicco, Giampaolo ^a   Favretto, Maria Silvia ^a   Scremin, Enrico ^a   Tambone, Carmelo ^a   Tasca, Andrea ^a   Guglielmi, Rosabianca ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Hypofractionation; Prostate cancer; PSA; Stereotactic body radiotherapy; Toxicity

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CYBERKNIFE; DISEASE SEVERITY; FOLLOW UP; HUMAN; MALE; PROSTATE CANCER; RATING SCALE; RECTUM HEMORRHAGE; STEREOTACTIC BODY RADIATION THERAPY; URINARY TRACT DISEASE;

EID: 78049312251     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303461000900505     Document Type: Article

References (18)

1. Levitt, S. H., Perez, C. A., Hui, S., Purdy, J. A. Evolution of computerized radiotherapy in radiation oncology: potential problems and solutions. Int J Radiat Oncol Biol Phys 70, 978-986 (2008). (Pubitemid 351296123)
2. Wurm, R., Okunieff, P. Intracranial and Extracranial Stereotactic Radiosurgery and Radiotherapy. Int J Radiat Oncol Biol Phys 66, S1-S2 (2006).
3. Ling, C. C., Yorke, E., Fuks, Z. From IMRT to IGRT: frontierland or neverland? Radiother Oncol 78, 119-122 (2006).
4. Ritter, M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 18, 249-256 (2008).
5. Fowler, J., Chappell, R., Ritter, M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50, 1021-1031 (2001).
6. Zelefsky, M. J., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C. C., Amols, H., Venkatraman, E. S., Leibel, S. A. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53, 1111-1116 (2002). (Pubitemid 34787844)
7. King, C. R., Lehmann, J., Adler, J. R., Hai, J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2, 25-29 (2003).
8. Kupelian, P. A., Willoughby, T. R., Reddy, C. A., Klein, E. A., Mahadevan, A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68, 1424-1430 (2007).
9. Friedland, J. L., Freeman, D. E., Masterson-McGary, M. E., Spellberg, D. M. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8, 387-392 (2009).
10. King, C. R., Brooks, J. D., Gill, H., Pawlicki, T., Cotrutz, C., Presti, J. C., Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73, 1043-1048 (2009).
11. Fuller, D. B., Naitoh, J., Lee, C., Hardy, S., Jin, H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70, 1588-1597 (2008).
12. Madsen, B. L., Hsi, R. A., Pham, H. T., Fowler, J. F., Esagui, L., Corman, J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67, 1099-1105 (2007). (Pubitemid 46320084)
13. Brenner, D. J. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 48, 315-316 (2000).
14. Fowler, J. F., Ritter, M. A., Chappell, R. J., Brenner, D. J. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56, 1093-1104 (2003).
15. Brenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D., Armour, E. P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52, 6-13 (2002).
16. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., Amols, H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176, 1415-1419 (2006).
17. Peeters, S. T., Heemsbergen, W. D., van Putten, W. L., Slot, A., Tabak, H., Mens, J. W., Lebesque, J. V., Koper, P. C. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61, 1019-1034 (2005). (Pubitemid 40340897)
18. Roach, M., 3rd, Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W. U., Sokol, G. H., Sandler, H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65, 965-974 (2006).